PRMT5 and familial pancreatic carcinoma: In addition, our study supported with previous publication that PRMT5 could be a novel marker for pancreatic cancer patients’ classification and potential therapeutic target, providing preclinical evidence that PRMT5 could be translated into a therapeutic target for treatment for pancreatic cancer.